A design for phase II testing of anticancer agents within a phase III clinical trial.

[1]  D. Schaid,et al.  The effect on survival of initial chemotherapy in advanced breast cancer: polychemotherapy versus single drug. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  T M Therneau,et al.  Designs for group sequential phase II clinical trials. , 1987, Biometrics.

[3]  S K Carter,et al.  Calibrated phase II clinical trials in oncology. , 1986, Statistics in medicine.

[4]  S S Ellenberg,et al.  Randomized phase II clinical trials. , 1985, Cancer treatment reports.

[5]  S Marsoni,et al.  The phase II trial. , 1985, Cancer treatment reports.

[6]  J. Ingle,et al.  Randomized clinical trial of doxorubicin alone or combined with mitolactol in women with advanced breast cancer and prior chemotherapy exposure , 1985, American journal of clinical oncology.

[7]  J. Ingle,et al.  Randomized clinical trial of cyclophosphamide, 5-FU, and prednisone with or without tamoxifen in postmenopausal women with advanced breast cancer. , 1985, Cancer treatment reports.

[8]  M. Palta,et al.  Consideration of covariates and stratification in sample size determination for survival time studies. , 1985, Journal of chronic diseases.

[9]  D. Schoenfeld,et al.  Sample-size formula for the proportional-hazards regression model. , 1983, Biometrics.

[10]  T R Fleming,et al.  One-sample multiple testing procedure for phase II clinical trials. , 1982, Biometrics.

[11]  D. Schoenfeld.  The asymptotic properties of nonparametric tests for comparing survival distributions , 1981 .

[12]  R. Simon,et al.  Two-stage plans for patient accrual in phase II cancer clinical trials. , 1979, Cancer treatment reports.

[13]  D. Ahmann,et al.  Phase II clinical trial of isophosphamide (NSC-109724) in patients with advances breast cancer. , 1974, Cancer chemotherapy reports.

[14]  D. Ahmann,et al.  Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer. , 1974, Cancer chemotherapy reports.

[15]  D. Ahmann,et al.  A phase 2 evaluation of 1-(2-chloroethyl)-3-(4- methylcyclohexyl)-1-nitrosourea (NSC 95441) in patients with advanced breast cancer. , 1974, Cancer research.

[16]  D. Ahmann,et al.  Difficulties designing clinical trials as exemplified by a phase 2 drug evaluation of 5(3,3-bis(2-chloroethyl)-1-triazenol)-imidazole-4-carboxamide and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in patients with disseminated breast cancer. , 1973, Cancer research.

[17]  J. Peto,et al.  Asymptotically Efficient Rank Invariant Test Procedures , 1972 .